Advertisement

Characterization of the Primary Structure of Cysteine-Linked Antibody-Drug Conjugates Using Capillary Electrophoresis with Mass Spectrometry

  • Josiane Saadé
  • Rabah Gahoual
  • Alain Beck
  • Emmanuelle Leize-Wagner
  • Yannis-Nicolas FrançoisEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2078)

Abstract

Capillary electrophoresis-mass spectrometry (CE-MS) enables the characterization of the primary structure of ADCs. An analytical method based on a derived bottom-up proteomic workflow is designed to provide detailed information about the amino acid sequence, the glycosylation profiling, and the location on the peptide backbone of the conjugated drugs. Here we describe the experimental protocol applied on the characterization of cysteine-linked brentuximab vedotin (Adcetris®).

Key words

Antibody-drug conjugate Brentuximab vedotin Cytotoxic drug Capillary electrophoresis–mass spectrometry Structural characterization Drug-loaded peptide 

Notes

Acknowledgments

The authors would like to thank Sciex separations Inc. for lending a CESI8000 system and a 5600 TripleTOF. They would like to thank Bruker Daltonics for lending a Maxis 4G. They would like also to express their gratitude to Dr. E. Wagner-Rousset, M. C. Janin-Bussat, and O. Colas (Centre d’Immunologie Pierre Fabre, St Julien en Genevois, France) for helpful discussions. This work was supported by the CNRS (UMR 7140) and the University of Strasbourg.

References

  1. 1.
    Beck A, Reichert JM (2014) Antibody-drug conjugates. MAbs 6(1):15–17CrossRefGoogle Scholar
  2. 2.
    Tvito A, Rowe JM (2017) Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia. Expert Opin Biol Ther 17(12):1557–1564CrossRefGoogle Scholar
  3. 3.
    Jen EY, Ko C-W, Lee JE et al (2018) FDA approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. Clin. Cancer Res 24(14):3242–3246Google Scholar
  4. 4.
    Beck A, Goetsch L, Dumontet C, Corvaïa N (2017) Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov 16:315CrossRefGoogle Scholar
  5. 5.
    Kaplon H, Reichert JM (2018) Antibodies to watch in 2018. MAbs 10(2):183–203CrossRefGoogle Scholar
  6. 6.
    Zolot RS, Basu S, Million RP (2013) Antibody-drug conjugates. Nat Rev Drug Discov 12(4):259–260CrossRefGoogle Scholar
  7. 7.
    Biacchi M, Gahoual R, Said N, Beck A, Leize-Wagner E, François Y-N (2015) Glycoform separation and characterization of Cetuximab variants by middle-up off-line capillary zone electrophoresis-UV/electrospray ionization-MS. Anal Chem 87(12):6240–6250CrossRefGoogle Scholar
  8. 8.
    Stoll DR, Hannes DC, Danforth J et al (2015) Direct identification of rituximab Main isoforms and subunit analysis by online selective comprehensive two-dimensional liquid chromatography-mass spectrometry. Anal Chem 87(16):8307–8315CrossRefGoogle Scholar
  9. 9.
    Debaene F, Boeuf A, Wagner-Rousset E et al (2014) Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM-MS for average DAR and DAR distribution assessment. Anal Chem 86(21):10674–10683CrossRefGoogle Scholar
  10. 10.
    Janin-Bussat M-C, Dillenbourg M, Corvaia N, Beck A, Klinguer-Hamour C (2015) Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC-MS analysis. J Chromatogr B 981:9–13CrossRefGoogle Scholar
  11. 11.
    Firth D, Bell L, Squires M, Estdale S, McKee C (2015) A rapid approach for characterization of thiol-conjugated antibody–drug conjugates and calculation of drug–antibody ratio by liquid chromatography mass spectrometry. Anal Biochem 485:34–42CrossRefGoogle Scholar
  12. 12.
    Gahoual R, Busnel J-M, Beck A, François Y-N, Leize-Wagner E (2014) Full antibody primary structure and microvariant characterization in a single injection using transient Isotachophoresis and Sheathless capillary electrophoresis–tandem mass spectrometry. Anal Chem 86(18):9074–9081CrossRefGoogle Scholar
  13. 13.
    Gahoual R, Burr A, Busnel JM et al (2013) Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. MAbs 5(3):479–490CrossRefGoogle Scholar
  14. 14.
    Gahoual R, Biacchi M, Chicher J et al (2014) Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry. MAbs 6(6):1464–1473CrossRefGoogle Scholar
  15. 15.
    Gahoual R, Beck A, Leize-Wagner E, François Y-N (2016) Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products. J Chromatogr B 1032:61–78CrossRefGoogle Scholar
  16. 16.
    Said N, Gahoual R, Kuhn L, Beck A, François Y-N, Leize-Wagner E (2016) Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis—tandem mass spectrometry as nanoESI infusion platform and separation method. Anal Chim Acta 918:50–59CrossRefGoogle Scholar
  17. 17.
    Giorgetti J, D’Atri V, Canonge J et al (2018) Monoclonal antibody N-glycosylation profiling using capillary electrophoresis—mass spectrometry: assessment and method validation. Talanta 178(Supplement C):530–537CrossRefGoogle Scholar
  18. 18.
    Dada OO, Zhao YM, Jaya N, Salas-Solano O (2017) High-resolution capillary zone electrophoresis with mass spectrometry peptide mapping of therapeutic proteins: peptide recovery and post-translational modification analysis in monoclonal antibodies and antibody-drug conjugates. Anal Chem 89(21):11236–11242CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Josiane Saadé
    • 1
  • Rabah Gahoual
    • 2
  • Alain Beck
    • 3
  • Emmanuelle Leize-Wagner
    • 1
  • Yannis-Nicolas François
    • 1
    Email author
  1. 1.Laboratoire de Spectrométrie de Masse des Interactions et des Systèmes (LSMIS), UMR 7140 (Unistra-CNRS)Université de StrasbourgStrasbourgFrance
  2. 2.Laboratoire Vecteurs Pour l’Imagerie Moléculaire et le Ciblage Thérapeutique (VICT), Faculté de PharmacieUniversité Paris DescartesParisFrance
  3. 3.Pierre Fabre LaboratoriesIRPF—Centre d’Immunologie Pierre Fabre (CIPF)Saint-Julien-en-GenevoisFrance

Personalised recommendations